Below are the most recent publications written about "Endothelin Receptor Antagonists" by people in Profiles.
-
Smith MP, Rowling EJ, Miskolczi Z, Ferguson J, Spoerri L, Haass NK, Sloss O, McEntegart S, Arozarena I, von Kriegsheim A, Rodriguez J, Brunton H, Kmarashev J, Levesque MP, Dummer R, Frederick DT, Andrews MC, Cooper ZA, Flaherty KT, Wargo JA, Wellbrock C. Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. EMBO Mol Med. 2017 08; 9(8):1011-1029.
-
Snarr BS, Paridon SM, Rychik J, Goldberg DJ. Pulmonary vasodilator therapy in the failing Fontan circulation: rationale and efficacy. Cardiol Young. 2015 Dec; 25(8):1489-92.
-
Bednov A, Espinoza J, Betancourt A, Vedernikov Y, Belfort M, Yallampalli C. L-arginine prevents hypoxia-induced vasoconstriction in dual-perfused human placental cotyledons. Placenta. 2015 Nov; 36(11):1254-9.
-
Carducci MA, Manola J, Nair SG, Liu G, Rousey S, Dutcher JP, Wilding G. Atrasentan in Patients With Advanced Renal Cell Carcinoma: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E6800). Clin Genitourin Cancer. 2015 Dec; 13(6):531-539.e1.
-
Kim SJ, Lee HJ, Kim MS, Choi HJ, He J, Wu Q, Aldape K, Weinberg JS, Yung WK, Conrad CA, Langley RR, Lehembre F, Regenass U, Fidler IJ. Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice. Clin Cancer Res. 2015 Oct 15; 21(20):4630-41.
-
Franklin WJ, Parekh DR, Safdar Z. Adult congenital heart disease and pulmonary arterial hypertension: the Texas Adult Congenital Heart Program experience. Postgrad Med. 2011 Nov; 123(6):32-45.
-
Tam Tam KB, George E, Cockrell K, Arany M, Speed J, Martin JN, Lamarca B, Granger JP. Endothelin type A receptor antagonist attenuates placental ischemia-induced hypertension and uterine vascular resistance. Am J Obstet Gynecol. 2011 Apr; 204(4):330.e1-4.
-
Kim SJ, Kim JS, Kim SW, Brantley E, Yun SJ, He J, Maya M, Zhang F, Wu Q, Lehembre F, Regenass U, Fidler IJ. Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer. Neoplasia. 2011 Feb; 13(2):167-79.
-
Li N, Jia N, Dai DZ, Hu C, Dai Y. Role of endothelin in the effects of isoprenaline on potassium currents and calsequestrin 2 expression in the heart. Clin Exp Pharmacol Physiol. 2010 May; 37(5-6):557-63.
-
Adatia I, Shekerdemian L. The role of calcium channel blockers, steroids, anticoagulation, antiplatelet drugs, and endothelin receptor antagonists. Pediatr Crit Care Med. 2010 Mar; 11(2 Suppl):S46-52.